Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 12:49.

Indivior PLC (GB00BYZ0C031) sits on the Nasdaq under the ticker INDV, with analysts using the U.S. venue as the main reference point for their earnings and valuation work. Consensus data and recent commentary provide a structured picture of expectations for the addiction-treatment specialist.

What analysts say about Indivior

Indivior is covered by several international houses, with brokers tracking its U.S. listing as Indivior Pharmaceuticals Inc. on Nasdaq and publishing estimates in U.S. dollars. According to MarketWatch, the company operates primarily in the United States, United Kingdom and Rest of World, giving analysts a diversified revenue base to model.

The profile data cited by MarketWatch describe Indivior as focused on buprenorphine-based prescription drugs for opioid dependence, a niche that attracts both healthcare specialists and generalist equity analysts. This framing feeds directly into earnings models, where U.S. demand for opioid-dependence therapy is a central driver for top-line projections.

How consensus frames earnings

Across broker platforms, consensus for Indivior typically aggregates estimates for revenue, operating margin and earnings per share over a three-year horizon. Analysts factor in patent life, competitive dynamics in addiction medicine and reimbursement frameworks in the United States and Europe when setting their numbers.

MarketWatch’s company profile highlights that Indivior’s operations are segmented into United States, Rest of World and United Kingdom, a structure that makes it easier for analysts to assign different growth and margin assumptions by region. This segmentation is particularly relevant when comparing Indivior to peers such as Viatris or generic manufacturers with broader therapy portfolios.

The product behind the stock

Indivior’s core business centers on medicines for opioid dependence, with buprenorphine-based brands such as Suboxone Film, Suboxone Tablet and Subutex Tablet listed in its corporate profile. These products generate the majority of revenue and underpin the cash flows analysts model for the Nasdaq-listed equity.

Where the stock trades today

Indivior PLC shares (GB00BYZ0C031) trade on Nasdaq under the ticker INDV; recent U.S. quote data from MarketWatch show the stock active on the exchange, with price and market capitalization updated on a rolling basis in U.S. dollars.

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources believed to be reliable at the time of publication.